FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 390 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Diagnosed With Breast Cancer At 24, Her Biggest Fear Wasn’t Death... October 10, 2019 Five Questions with…Debra. March 31, 2022 Adding Atezolizumab to Cabozantinib Fails to Improve Clinical Outcomes and Increases... June 13, 2023 Today is Random Acts of Kindness Day February 17, 2021 Load more HOT NEWS Development of Secondary T-Cell Cancers After the Use of CAR T-Cells... Breast Cancer Warrior’s Emotional Photoshoot Features Her Husband Shaving Her Head FDA Grants Accelerated Approval to Naxitamab for High-Risk Neuroblastoma in Bone... Evaluation of Primary and Secondary Prevention of Oral Cancer
